The US-based drug maker Eli Lilly and Company will form strategic drug manufacturing and development alliances with major Indian pharmaceutical companies to tap the opportunities in contract research and manufacturing.
US-based pharma giants Eli Lilly and company has filed a case against two Indian drug makers, Aurobindo Pharma and Lupin alleging infringement of patent of its anti-depressant drug Cymbalta.
Eli Lilly and Company, the US-based multinational pharmaceutical major, has sued Sun Pharmaceuticals in the US, alleging the company infringed its patent on Gemzar, a blockbuster cancer drug.
Pharma major Nicholas Piramal India Ltd will develop and commercialise a select group of US-based Eli Lilly and Company's pre-clinical drug products that span multiple therapeutic areas.
Drug major Eli Lilly will discontinue its animal insulin product "Iletin" after this year and is planning to conduct trials for "inhaled insulin" in the country.
Delhi-based Eli Lilly & Company (India) Pvt Ltd has cut by 40 per cent the price of 'Xigris,' used for treating food poisoning in line with reduced customs duty.
In another setback to Big Pharma, US drug major Eli Lilly's blockbuster erectile dysfunction drug Cialis (generic name:Tadalafil) has failed to qualify for a product patent in India after the basic constituent of the medicine was found to be a known substance, developed and patented by Indian scientists 32 years ago.
Suven Life Sciences Ltd has signed an agreement with US-based pharmaceutical firm Eli Lilly and Company to carryout pre-clinical research for central nervous system disorder.
US-based pharmaceutical major Eli Lilly on Thursday announced a $70 million initiative as part of its effort to combat the spread of Multi-Drug Resistant Tuberculosis in India and other developing countries.
India's largest IT services firm Tata Consultancy Services on Wednesday said it won a contract from Eli Lilly to provide various drug development services to the US pharma firm.
Global pharmaceutical major Eli Lilly is exploring the possibility of introducing more products from its global portfolio in India.
The company is entering into 'risk and reward sharing arrangements' with Indian drug makers which are converting from a generic model to one based on R&D.
On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.
Domestic pharma firm inks first-of-its-kind pact.
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.
For patients, the immediate impact is a reduction in the final cost of therapies that often run into lakhs per month.
Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.
The bumper rise is due to the rising demand for the drug and patients' gradual shift towards its higher dosage.
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.
The 23-time Grand Slam champion, who retired from professional tennis in 2022, will headline a multi-year national marketing campaign for GLP-1 drugs, a company spokesperson said.
'Willingness to try new drugs for obesity management have propelled the growth of this market, which today is almost five times what it was five years ago.'
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
The $1.2 billion in-space manufacturing market is expected to grow and be worth more than $20 billion by 2033.
Department of Pharmaceuticals asks NPPA to review Eli Lilly product prices.
The drug regulator recently asked some domestic companies to cut prices of insulin while MNCs, which are major players, are allowed to set their own price for the drug.
The ministry has asked 44 pharmaceutical companies, including global drug majors such as Eli Lilly, Novartis, Pfizer, Bayer, Merck, Johnson & Johnson and Sanofi Aventis, to explain why they have not given the compensation, which is mandatory under the current drug laws.
Another cap for imported insulin; domestic manufacturers cry foul.
Prime Minister Narendra Modi urged CEOs of US majors to take advantage of India's growth story as the country is making all efforts to become the third largest economy of the world in his third term. India is currently the fifth largest economy of the world after the US, China, Germany and Japan with a GDP of around $3.9 trillion. India has been the fastest growing large economies of the world with GDP growth rate of over 7 per cent for the last three consecutive years.
The medicines whose prices have been reduced belong to therapeutic categories, like dexametozone, betamethazone, ampicillin and ranitidine. The prices of some multi-vitamins and antibiotics would rise a bit.
Major drug discovery outsourcing deals have almost dried up in the past 18 months for almost all prominent players in the area
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances